Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Current Deferred Revenue: 2010-2024

Historic Current Deferred Revenue for Cryo Cell International (CCEL) over the last 15 years, with FY2024 value amounting to $56.3 million.

  • Cryo Cell International's Current Deferred Revenue rose 828.57% to $59.6 million in Q3 2025 from the same period last year, while for Aug 2025 it was $59.6 million, marking a year-over-year increase of 828.57%. This contributed to the annual value of $56.3 million for FY2024, which is 1071.74% up from last year.
  • Latest data reveals that Cryo Cell International reported Current Deferred Revenue of $56.3 million as of FY2024, which was up 1071.74% from $50.9 million recorded in FY2023.
  • Cryo Cell International's 5-year Current Deferred Revenue high stood at $56.3 million for FY2024, and its period low was $36.4 million during FY2020.
  • For the 5-year period, Cryo Cell International's Current Deferred Revenue averaged around $46.0 million, with its median value being $45.6 million (2022).
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first surged by 1219.08% in 2022, then surged by 1071.74% in 2024.
  • Over the past 5 years, Cryo Cell International's Current Deferred Revenue (Annual) stood at $36.4 million in 2020, then rose by 11.68% to $40.6 million in 2021, then rose by 12.19% to $45.6 million in 2022, then rose by 11.64% to $50.9 million in 2023, then grew by 10.72% to $56.3 million in 2024.
  • Its Current Deferred Revenue stands at $56.3 million for FY2024, versus $50.9 million for FY2023 and $45.6 million for FY2022.